neuropsychiatric disease

Luminex said its technology will enhance the processing speed and capacity of Assurex's tests.

NEW YORK (GenomeWeb) – Assurex Health today said that the US Department of Veterans Affairs has approved the firm's GeneSight Psychotropic test for use in VA facilities nationwide.

NEW YORK (GenomeWeb News) – Emory University said on Tuesday that it will lead an effort to sequence the genomes of 1,000 people who suffer from 22q11.2 deletion syndrome as part of an international consortium that has received $12 million from the National Institute of Mental Health to study how

NEW YORK (GenomeWeb News) – The National Institute of Mental Health will award around $3 million to fund as many as six projects that pursue research into a genetic microdeletion that has been associated with a range of neuropsychiatric disorders.

NEW YORK (GenomeWeb News) – Pharmacogenomics firm AssureRx Health announced on Wednesday it has closed its Series C financing, raising $12.5 million.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – A public-private consortium to generate and analyze large-scale genomic data from patients with neuropsychiatric diseases has launched.

The Welsh government has awarded over $9 million for a new mental health research center, cancer genetics studies, and a new imaging unit.

The firm's GeneSightRx technology uses DNA from a cheek swab to measure and analyze genetic variants to determine how a patient will respond to psychotropic medications.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.